Immunome, Inc.
IMNM · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.30 | -0.03 | -0.02 | -0.23 |
| FCF Yield | -18.94% | -3.96% | -107.98% | -12.24% |
| EV / EBITDA | -3.20 | -4.12 | -0.19 | -4.20 |
| Quality | ||||
| ROIC | -164.41% | -86.23% | -221.42% | -51.95% |
| Gross Margin | 100.00% | 100.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.38 | 0.07 | 0.78 | 0.74 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -1,304.54% | 70.98% | -58.09% | -43.91% |
| Safety | ||||
| Net Debt / EBITDA | 0.92 | 3.47 | 0.55 | 2.04 |
| Interest Coverage | 0.00 | 0.00 | -7,380.20 | -2,520.40 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -1,652.52 | -1,388.27 | -1,487.56 |